<DOC>
	<DOCNO>NCT00475865</DOCNO>
	<brief_summary>The primary objective estimate tolerability safety 2 dos Teriflunomide administer daily 24 week , compare placebo , patient multiple sclerosis [ MS ] relapse stable dose Glatiramer Acetate [ GA ] . The secondary objective : - estimate effect 2 dos Teriflunomide , compare placebo , combination stable dose GA Magnetic Resonance Imaging [ MRI ] parameter , relapse rate patient-reported fatigue ; - perform pharmacokinetic analysis 2 dos teriflunomide combination stable dose GA .</brief_summary>
	<brief_title>Phase II Study Teriflunomide Adjunctive Therapy Glatiramer Acetate Subjects With Multiple Sclerosis</brief_title>
	<detailed_description>The duration study period participant approximatively 44 week broken follow : - Screening period 4 week , - 24-week double-blind treatment period* , - 16-week post-treatment elimination follow-up period . '* ' Participants successfully complete week 24 visit offer opportunity enter optional long-term extension study LTS6047 - NCT00811395 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Definite MS diagnosis accord McDonald 's criterion ; Relapsing clinical course , without progression ; Expanded Disability Status Scale [ EDSS ] less equal 5.5 ( ambulatory ) ; Stable dose Glatiramer Acetate [ GA ] least 26 week prior screen visit ; No onset MS relapse precede 60 day prior randomization ; Clinically stable 4 week prior randomization . Other chronic disease immune system , liver function impairment chronic pancreatic disease ; Pregnant nursing woman ; Alcohol drug abuse ; Use cladribine , Mitoxantrone , immunosuppressant agent Azathioprine , Cyclophosphamide , Cyclosporin , Methotrexate Mycophenolate enrollment ; Human immunodeficiency virus [ HIV ] positive status ; Any known condition circumstance would prevent investigator 's opinion compliance completion study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>MS</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>relapse</keyword>
</DOC>